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Abstract
Background: The application of spacer gel represents a promising approach to reliably spare the rectal frontal wall
during particle therapy (IJROBP 76:1251-1258, 2010). In order to qualify the spacer gel for the clinical use in particle
therapy, a variety of measurements were performed in order to ensure the biological compatibility of the gel, its
physical stability during and after the irradiation, and a proper definition of the gel in terms of the Hounsfield Unit (HU)
values for the treatment planning system. The potential for the use of the spacer gel for particle therapy monitoring
with off-line Positron Emission Tomography (PET) was also investigated.
Results: The spacer gel implanted to the prostate patient in direct neighbourhood to the clinical target volume does
not interfere with the particle therapy treatment planning procedure applied at Heidelberg Ion Beam Therapy Centre
(HIT). The performed measurements show that Bragg-peak position of the particles can be properly predicted on the
basis of computed tomography imaging with the treatment planning system used at HIT (measured water equivalent
path length of 1.011±0.011 (2σ ), measured Hounsfield Unit of 28.9±6.1 (2σ )). The spacer gel samples remain
physically unchanged after irradiation with a dose exceeding the therapeutic dose level. The independently measured
Bragg-Peak position does not change within the time interval of 10 weeks.
Conclusions: As a result of the presented experiments, the first clinical application of spacer gel implant during
prostate cancer treatment with carbon ions and protons was possible at HIT in 2012. The reported pre-clinical
investigations demonstrate that use of spacer gel is safe in particle therapy in presence of therapy target motion and
patient positioning induced particle range variations. The spacer gel injected between prostate and rectum enlarge
the distance between both organs, which is expected to clinically significantly decrease the undesirable exposure of
the most critical organ at risk, i.e. rectal frontal wall. Further research on the composition of spacer gel material might
lead to additional clinical benefits by validation of particle therapy of prostate via post-therapeutic PET-imaging or by
patient positioning based on the gel as a radio-opaque marker.
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Background
Prostate cancer is the predominant cancer in men in
developed countries. Clinical trials for intensity modu-
lated radiation therapy (IMRT) demonstrated that the
increase of the target dose for prostate cancer enables
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better tumour control [1,2]. In order to guarantee a suc-
cessful therapy, the clinical target volume must be entirely
covered by the prescribed dose during all treatment frac-
tions. In clinical practice, limitations in the accuracy of
the treatment delivery are often dealt with by enlarging
safety margins around the target volume. This margin
extension strongly depends on the applied radiation tech-
nique, availability of image guidance and selection of the
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patient positioning protocol, inter- and intrafractional tar-
get motion, and dose-exposure limits of neighbouring
organs at risk.
Carbon ion therapy is expected to be an efficient
method for treating prostate cancer due to its high con-
formity and radiobiological effectiveness [3,4]. The high
conformity in particle therapy is challenged by organ
motion that may strongly affect the target dose distri-
bution. A variety of studies have already reported the
impact of intra- and interfractional prostate motion on
the precision of photon radiotherapy, e.g. [5-7]. Due to
the finite range of the ions in tissue, further deviations
in the target dose may occur as a result of variations in
material density distribution over the particle path mainly
induced by daily target motion and patient positioning [8].
For pre-treatment patient positioning the Heidelberg
Ion Beam Therapy Centre, Heidelberg, Germany (HIT)
offers image guided radiation therapy based on a dig-
ital X-ray system. This implies the application of a
bony anatomy registration protocol for the positioning
of prostate cancer patients. The clinical target volume
(CTV), i.e. prostate, is located between two organs at
risk (OAR): rectum and bladder. Due to the day-to-
day target motion, the rectal frontal wall may shift into
the high dose region of the field previously defined
for the target volume. This leads to unquantified expo-
sure of rectum and may result in rectal toxicity [6].
The tendency to apply a hypofractionated prostate treat-
ment protocol emphasises this problem [9,10]. For these
reasons the application of soft tissue like spacer gel
(SpaceOAR™System, Augmenix Inc., Waltham, MA, US)
enlarging the distance between radiotherapy target and
organ at risk [11], not inducing particle range vari-
ations, represents a promising approach to reliably
spare the rectal frontal wall during particle therapy. At
HIT first prostate patients were treated with scanned
carbon ion and proton beams using spacer gel in
early 2012.
In order to qualify the spacer gel for the clinical use, a
variety of measurements is required to guarantee the bio-
logical compatibility of the gel, its physical and chemical
stability during and after the irradiation, and a proper def-
inition of the gel in terms of Hounsfield Unit (HU) values
for the treatment planning system (TPS). The potential
for the use of the spacer gel for particle therapy moni-
toring with offline Positron Emission Tomography (PET)
is also an issue of interest. This paper reports on the
set of measurements performed in collaboration of Aug-
menix Inc., Waltham, MA, US, and HIT. The presented
results and the clinical experience of Heidelberg Univer-
sity Clinic in application of spacer gel in photon radio-
therapy are the basis for the first application of spacer
gel during prostate therapy with carbon ions and protons
at HIT.
Bio-compatibility of the spacer gel implant
The SpaceOAR hydrogel consists primarily of water and
crosslinked polyethylene glycol (PEG). PEG is widely
used in the pharmaceutical, cosmetic and medical device
industries due to its low toxicity and lack of immuno-
genicity. In use, the SpaceOAR hydrogel is applied into
the potential space betweenDennonvilliers’ Fascia and the
frontal rectal wall under transrectal ultrasound guidance.
Following placement of an 18G needle, the liquid hydro-
gel precursors are injected, expanding the space. Within
10 seconds ester linkages on the PEG crosslink with amine
endgroups on trilysine, causing the hydrogel to polymer-
ize (solidify) without a measurable rise in temperature.
The ester at each PEG-trilysine linkage is water sensitive,
allowing the network to hydrolyze and liquefy over time.
The kinetics of this hydrolysis are such that the hydrogel
remains in place for three months, after which it lique-
fies, is absorbed, and cleared via renal filtration within six
months of implantation.
Prior to clinical evaluation the SpaceOAR hydrogel
underwent extensive biocompatibility testing per ISO
10993 (International Organization for Standardization,
http://www.iso.org/) performed at Augmenix. To evalu-
ate the potential effects of irradiation on hydrogel com-
patibility, tests were performed on gels with exposure
to 150Gy photon irradiation, and on gels with no irra-
diation. Augmenix reports that, as anticipated, the gel
was found to be non-cytotoxic, non-sensitizing, non-
genotoxic, and with no signs of local or systemic tox-
icity, even at high doses. In a 16-week intramuscular
test on the rabbit, the hydrogel was rated as a non-
irritant, the same as the negative control high density
polyethylene.
Treatment planning
Predicting the energy loss of charged particles and
their respective range in the patient’s body (physically
described by the position of the Bragg-Peak) is one of
the objectives of radiotherapy planning with particles [12].
The treatment plan is calculated starting from Computed
Tomography (CT) images containing information about
the electron density distribution in the human body given
in HU values. On the basis of the spatial distribution
of HU values within the CT image the particle range in
material is predicted by a semiempirical scaling to the
particle range in water by means of the WEPL (water
equivalent path length) calibration. The relation of the
HU values to WEPL (defined as Hounsfield unit Look
Up Tables - HLUT) is the basis for treatment plan opti-
misation and dose determination. The piecewise linear
function HLUT is empirically estimated bymeasuring HU
values and particle ranges (WEPL) of tissue-equivalent
materials using the stoichiometric method [13]. For this
reason the safe application of the non-tissue implant of
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spacer gel in the area of the planning target volume (PTV)
requires that the range of the particles crossing the gel
during the irradiation is the same as their expected range
estimated by the TPS (on the basis of CT scan andHLUT).
The HU value of the spacer gel sample was determined
at the CT scanner commissioned for treatment planning
at HIT. The WEPL of the spacer gel was experimentally
estimated with water absorber of varying thickness [14]
in measurements at different points in time and in an
additional measurement after exposure to the high dose.
These verifications are crucial to ensure that the spacer
gel implant holds its original properties as assumed by
the treatment planning over the whole therapy course.
On the basis of these investigations the compatibility
of the spacer gel stopping properties with the HLUT
used for patient treatment plan optimisation at HIT was
validated.
Application for marking purposes
Beyond its main task, i.e. the spacer gel being implanted
in the direct proximity of the actual treatment vol-
ume but not being involved in biological processes,
it might also be exploited for marking purposes, for
example in PET-based treatment monitoring or as a
marker for patient pre-treatment positioning using X-ray
imaging.
At HIT, post-therapeutic PET measurements are per-
formed for in-vivo treatment verification [15]. Within the
irradiated volume, β+ emitting isotopes are produced in
inelastic fragmentation reactions between the beam par-
ticles and the tissue. The induced activity is measured
offline with a commercial PET/CT scanner subsequent
to the treatment fraction with a few minutes of delay
due to patient transportation to the scanner (located
next door to the treatment rooms) and repositioning.
Correlating the measured activity distribution to an
expectation calculated under the assumption of a correct
treatment delivery allows verifying the beam position and
the beam range in the target volume in suitable tissue
regions [16,17]. Owing to the human tissue composition
and the half-life of the produced isotopes, the obtained
activity image is dominated by 11C (T1/2 ≈ 1222 s), with
smaller contributions of 15O (T1/2 ≈ 120 s), 13N (T1/2 ≈
598 s) and 38K (T1/2 ≈ 458 s).
Due to the tissue-equivalence of the known chemical
composition of the spacer gel (c.f., Section Spacer gel sam-
ples) it is expected to be activated in a similar way as the
surrounding patient tissue. However, in contrast to the
natural tissue, where the induced activity is washed out
by physiological processes, which reduces significantly
the measurable signal level, the isotopes generated in the
spacer gel are locally confined to the production spot.
Due to this fact, the offline PET/CT-based monitoring
of the prostate patients potentially enables the usage of
the activated spacer gel as an in-vivo marker for inter-
fractional positioning verification. The level of activity
induced in the irradiation of the spacer gel is expected
to be comparatively low, since 15O is the most abun-
dantly generated isotope, which, however, decays to a
large extent during the time delay between end of irra-
diation and start of PET measurement. Nevertheless,
a study of the isotope separation in experimental data
provides valuable information to validate the chemi-
cal gel composition and to investigate the benefit of
the gel as a potential activity marker based on realis-
tic patient treatment scenarios. In the present study we
report the pre-clinical phantom studies, conducted at HIT




The spacer gel injected to the patient polymerises in
seconds and creates a volume of about 10 ml. The com-
position of the gel designed by Augmenix is 90% water
and 10% polyethylene glycol (PEG, chemical composi-
tion: C2H6O2) yielding only a low contrast against the
surrounding tissue on CT images. For the range mea-
surement the gel implant was injected into a plexiglass
(PMMA) vial manufactured for the experiment and closed
to the air by a precisely fitted cap. The vial creates the
cylindrical space for the spacer gel sample of 20mm diam-
eter and 32mm length which result in 10.05ml volume.
The vial made of PMMA was designed to be water-
tight after the caps are locked. In order to guarantee
exact positioning of the vial for the experiment in a
dedicated vial holder, the vial was manufactured with
an overall tolerance of 0.05mm (including axial toler-
ance of outer surface, planarity of the vial cap surfaces
involved in beam rangemeasurement). Assuming aWEPL
of one millimetre PMMA material of 1.165mmH2O
[18] the WEPL of two caps (2 x 6.85mm) is 15.96
mmH2O.
Other vials, empty and filled with distilled water, were
used for reference measurements. The same gel sample
was also adapted for the high dose exposure test described
in Section High dose irradiation.
In order to assess the effects of irradiation on SpaceOAR
hydrogel, further samples were dedicated for functional
and chemical tests performed by Augmenix before and
after an exposure to 150Gy photon irradiation, and to
33Gy carbon ion and 91Gy proton irradiation. The design
of the samples used in these tests does not impact the
quality of results; thus it is not described here.
Particle range measurement
Measurements of the particle range in the spacer gel
samples were performed with a PEAKFINDER Water
Rucin´ski et al. Radiation Oncology 2013, 8:134 Page 4 of 12
http://www.ro-journal.com/content/8/1/134
Figure 1 Schematic view on the spacer-gel range measurement setup. Using the three plane laser system indicating the beam line and the
isocentre a vial containing the gel sample (inserted in the vial holder) was positioned axisymmetric to the horizontal beam line. In order to minimise
effects of lateral scattering of particles the distance from the beam exit to the water column was minimised.
Column (PTW, Freiburg, Germany), a water absorber of
varying thickness (water column installed between two
parallel-plane ionisation chambers) commonly used for
experimental determination of the WEPL of materials.
The samples were positioned upstream to a water
absorber as it is schematically drawn in Figure 1. Within
one measurement session the cylindrical vial contain-
ing gel sample was rotated axially to the beam line
in the vial holder causing penetration of the sam-
ple at slightly different positions. The position of the
Bragg-Peak was estimated by varying the water col-
umn thickness and measuring the ratio of the charge
deposited in the ionisation chambers as described in
[18]. The range measurements were performed with car-
bon ion pencil beams with an energy of 200MeV/u,
a Gaussian focus profile of 5.1mm full width at half
maximum (FWHM), and an intensity of 5.0 · 106
particles/s.
In order to investigate the stability of the particle pen-
etration depth in the gel sample over time (treatment
course), the measurement session was repeated three
times within 10 weeks. A measurement session covered
reference measurements and measurement series of the
vial filled with spacer gel. The reference measurements
contained: (i) range measurement without any absorber,
(ii) in presence of an empty holder, (iii) in presence of a
holder with an empty vial, and (iv) with the vial filled with
water. In order to verify the quality of the reference mea-
surements, normalisation was performed with respect to
the calculated values. It was expected that after normalisa-
tion the reference measurements obtained during various
sessions give maximal error not larger than the error
of single acquisitions with water column (0.2mmH2O).
Putting the spacer gel sample in the field of the beam
causes a water equivalent shift of the reference Bragg-Peak
position, which is the basis for calculating the absolute
WEPL of the spacer gel:
WEPLgel = 1 + (vialw − vialg)d (1)
whereas:
WEPLgel - calculated water equivalent path length for
the gel sample,
vialw - Bragg-Peak position measured for the vial
filled with water,
vialg - Bragg-Peak position measured for the vial
filled with spacer gel,
d - thickness of the tested material in mm (without
top and bottom vial cap).
Since WEPL of the spacer gel was estimated in a rel-
ative way with respect to the reference measurement
performed with vial filled with water (vialw), the normal-
isation procedure has a verification purpose and does not
influence the calculatedWEPLgel.
The HU value of the spacer gel sample was estimated
using CT unit of the Siemens Biograph mCT scanner [19]
(later called HIT-PET/CT) being commissioned for treat-
ment planning at HIT. The scan was performed using
the body protocol, that is also applied during treatment
planning of prostate patients at HIT: body reconstruction
kernel (B40s), a tube output voltage of 120 kV, an inte-
grated current of 255mAs, and a reconstruction diameter
of 500mm. The vial containing the spacer gel used for
the range measurement was positioned in the centre of
a spherical PMMA phantom with a diameter of 16 cm.
The phantom was positioned centrally in the field of view
(FOV) of the scanner. The pixel spacing of the obtained
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images was 0.6055mm, whereas the slice thickness was
3mm. The HU value of the gel was determined with
Siemens RT planning software package (version VA11A).
A circular region of interest covering the spacer gel
(15mm diameter) was drawn on multiple slices and the
average HU value including the standard deviation was
calculated by the system.
High dose irradiation
In order to investigate the stability of the spacer gel
properties after exposure to a high dose, both the gel
sample dedicated for range measurements (after closing
particle penetration depth measurement session) and the
gel sample provided by Augmenix were exposed to a dose
exceeding the dose level that is applied in clinical stud-
ies on prostate cancer at HIT. Two irradiation plans were
generated with TRiP98 [12] software package (Treatment
Planning for Particles, developed at GSI Helmholtz Zen-
trum fur Schwerionenforschung, Darmstadt, Germany).
For both, carbon ions and protons, the RBE weighted dose
of 100Gy (RBE), delivered in one irradiation, was pre-
scribed to the target, whereas the actual clinical protocol
prescribes 66Gy (RBE), delivered in 20 fractions to the
clinical target volume.
In order to relate the clinical prostate patient irradi-
ation conditions to experimental gel sample irradiation
conditions (required due to direct neighbourhood of clin-
ical target volume and investigated material of spacer gel),
constant radiobiological effectiveness (RBE) values of 3
for carbon ions and 1.1 for protons were conservatively
assumed. These RBE values result mainly from α/β tissue
characteristic ratio applied in treatment planning in the









with the photon absorbed dose Dγ (typically 250 kV X-
rays) and the RBE weighted dose DIon, the carbon ions
or protons absorbed (physical) dose was calculated by
linking it to the photon absorbed dose (Dγ ) and used
as treatment plan optimisation constraint. The resulting
treatment plan specification for both ion species is sum-
marised in Table 1. The gel sample was positioned in
the centre of the planned target field. The isocentre of
the plan was set in the centre of mass of the target vol-
ume cube. The beam was entering along the z direction.
The high dose irradiation setup used for all gel samples is
schematically reported in Figure 2.
The fully 3D active raster scanning system with feed-
back from the monitors to the scanning system is used
for dose delivery at HIT [20]. During irradiation the ther-
apy control system verified in real-time the lateral position
of the beam and the delivered dose according to the pre-
scribed plan. To ensure that the samples were positioned
correctly according to the beam line, a set of radiographic
films was additionally positioned up- and downstream of
the vial.
PET measurement
Phantom design and experimental setup
The phantom was designed in such a way that the already
investigated materials, providing a reference medium,
were combined with gel samples specifically manufac-
tured with a dedicated geometry. A sketch of the phantom
design is presented in Figure 3. A box of (10x10x35) cm3
inner dimensionmade of PMMAplates of 1 cmwall thick-
ness was equipped with several transversely positioned
PMMA slabs of various thickness, building a slot where
the gel sample was fit in (c.f., Figure 3). The gel insert was
positioned in the plateau region of the expected activity
depth distribution, i.e. well in front of the distal activ-
ity falloff, to reduce uncertainties. The residual volume
in depth was filled with gelatin, used as a substitute for
water. For the production of the gel sample two dedi-
cated moulds were prepared and sent to Augmenix, where
the gel was filled in, resulting in rectangular shaped sam-
ples of about (2x4x10) cm3. Two identical phantoms were
assembled according to the design reported in Figure 3
and irradiated with mono-energetic proton pencil-beams
at two different energies, with the beam entering at the
PMMA-equipped side. For the irradiation, they were posi-
tioned at the centre of overall phantom length and gel
height at the laser-indicated iso-centre. After irradiation,
the phantoms were transported to the PET/CT device
(Siemens Biograph mCT), installed next room and again
positioned at the iso-centre. The examination protocol
comprises a 30 minute PET acquisition followed by the
Table 1 Treatment plan specification used for 12C and
proton high dose irradiation
12C Protons
Prescribed RBE weighted dose 100Gy (RBE) 100 Gy (RBE)
RBE 3 1.1
Absorbed target dose 33 Gy 91 Gy
Target field dimensions(*) X/Y/Z [mm]
Augmenix sample 25/65/25 25/65/25
Target field dimensions(*) X/Y/Z [mm]
HIT sample 32/55/40 -
Beam spot FWHM 6mm 12mm
The target fields in the irradiation plans were designed using safety margins
around the target in order to guarantee complete coverage of the sample with
the prescribed dose distribution. (*) Dimensions are defined in the beam
coordinate system (c.f., Figure 2).
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Figure 2 Schematic drawing of the irradiation setup used for high dose irradiation. The gel samples were positioned at “X“. The control films
were used for irradiation verification.
CT scan of the phantom, which is required for attenuation
correction in the PET image reconstruction.
Activity calculation and data analysis
The expected spatial positron emitter yield is simulated
using the Monte Carlo (MC) particle transport and inter-
action code FLUKA [21,22]. In view of the production
of β+-emitting isotopes, the approach reported in [23] is
applied to simulate the yields of 11C, 13N and 15O. In this
approach, externally provided production cross sections
for the different isotope production channels are coupled
to the actual code. The cross-section data sets used in
the present study have been validated experimentally at
HIT and tuned to model explicitly the proton-irradiation
induced activity yield measured with the installed PET
device. The material definition of the spacer gel for the
simulation was assumed as reported in Section Spacer
gel samples. In order to calculate the activity distribution
from the simulated positron emitter yield, the detailed
time structure of the irradiation and the subsequent time
delay to the 30 min PET acquisition is considered as
described in (Bauer J, Unholtz D, Kurz C, Parodi K: An
experimental approach to validate the Monte Carlo mod-
elling of offline PET/CT-imaging of positron emitters
induced by scanned proton beams, in preparation).
PET images are reconstructed from the measured
data by an iterative OSEM (ordered subset expecta-
tion maximization)-based algorithm provided by the
scannersoftware. For the data analysis, the same strategy
as described in (Bauer J, Unholtz D, Kurz C, Parodi K:
An experimental approach to validate the Monte Carlo
modelling of offline PET/CT-imaging of positron emit-
ters induced by scanned proton beams, in preparation) is
pursued, considering the reconstructed static PET image
in comparison to the total simulated activity distribution
as well as several dynamically reconstructed PET images
representing different time points within the total acquisi-
tion time. In the latter case, the initial activity contribution
Figure 3 Schematic drawing of the phantom design used for the PET study. Several PMMA plates were inserted into a PMMA box, with the
spacer gel sample in between. The remaining space downstream the beam direction was filled with gelatin. The phantom was positioned such that
the pencil beam entered the geometrical centre of the gel sample.
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of a single isotope fraction at the start of the PET mea-
surement is extracted by fitting the exponential activity
decay assuming the presence of the respective isotopes
in each material. In order to provide the maximum data
statistics, the activity distributions are laterally integrated
prior to the fit procedure. As the simulated activity yield
depends directly on the material definition, a compari-
son of the simulated to the experimentally determined




Table 2 summarises the obtained results of particle range
measurements under reference conditions and in the gel.
The results of the reference measurements obtained in
measurement session 1, 2 and 3 were normalised on
the basis of the range measurement performed without
any absorber to calculated value (applied offsets were:
0.00mmH2O, -0.03mmH2O and 0.69mmH2O, respec-
tively). For the reference measurements in the empty vial
and in the vial filled with water (#3-#4) the calculated
values of Bragg-Peak position are covered by 2 σ field
(± 0.2mmH2O) of experimentally estimated carbon ion
depths. The positions of the Bragg-Peak obtained with the
vial filled with water and with spacer gel almost overlap.
The relative shift is 0.39± 0.49mmH2O maximally. The
measured mean particle range in the vial filled with gel in
all three measurement sets is 38.31±0.28 (2σ )mmH2O,
which results in WEPL of 1.011±0.011 (2σ ). As the vari-
ation of the Bragg-Peak position for the spacer gel and for
water is of the same magnitude within all three measure-
ment sessions, one can conclude that no relevant changes
in the range of carbon ions in the gel were observed within
10 weeks period.
In order to analyse the compatibility of the spacer gel
with the TPS at HIT, the HU value of the spacer gel was
determined using HIT-PET/CT by 28.9 ± 6.1 (2σ ), c.f.,
Figure 4, which, in accordance with HLUT used at HIT,
corresponds to WEPL of 1.027. On the basis of treatment
planning CT image, the TPS assumes a WEPL for the
particle range calculation insignificantly larger than real
particle range during the irradiation. The difference of the
measured (real) WEPL of spacer gel to the predicted one
(based on CT) is 0.016.
Insensitivity to high dose irradiation
The spacer gel insensitivity to high dose irradiation was
independently investigated by Augmenix and at HIT. The
analysis performed at HIT indicated that no particle range
changes could be observed due to the exposure of the
sample to the absorbed dose of 33Gy (carbon ions), and
91Gy (protons). These doses are comparable to 100Gy
(RBE) in target area of prostate patient. The measured
mean particle range in the vial filled with gel after the
high dose irradiation was 38.37±0.51 (2σ )mmH2O and
thus differs from the mean value determined prior to the
high dose exposure by 0.06mmH2O (c.f., Table 2, ses-
sion 3, measurements #5 and #6). The difference in mean
value is insignificant with regard to measurement uncer-
tainties, which indicates that the larger standard deviation
calculated for peak position measurement obtained after
the high dose irradiation in comparison to the previous
ones might have been caused by positioning uncertainties.
PET Measurement
The two PET phantoms containing the spacer gel (c.f.,
Figure 3) were irradiated with mono-energetic pencil-
like proton beams of E = 125.67MeV/u and E =
176.75MeV/u, which reflect a medium ∼12 cm and
∼21 cm deep (penetration depth in water) and were
already used in previous measurements in PMMA
and gelatin material (Bauer J, Unholtz D, Kurz C,
Parodi K: An experimental approach to validate the
Table 2 Calculated [24] andmeasured carbon ion ranges (presented inmm)
Calculated Session 1 Session 2 Session 3
#1 Reference 86.65 86.65 86.68 85.96
#2 Phantom-reference 86.65 86.61 86.69 85.97
#3 Empty vial 70.69 70.80 70.80 70.00
#4 Vial filled with water 38.51 38.71 38.72 38.02
#5 Vial filled with gel - [3] 38.31 ±0.30 [5] 38.27 ±0.29 [3] 37.63 ±0.29
#6 Vial filled with gel - - - [3] 37.68 ±0.51
(After 33Gy irradiation)
#7 WEPL of spacer gel - 1.0126 ±0.0111 1.0141 ±0.0101 1.082 ±0.0108
Sessions 1–3 (columns) refer to three measurement series acquired within 10 weeks. The values in rows #1 to #6 are given in mmH2O. Rows #1 to #4 present the
ranges acquired in reference measurements (2σ = 0.2mmH2O), row #5 (2σ uncertainty) reports the measured ranges of spacer gel, row #6 (2σ uncertainty) the
measured range after the high dose irradiation (c.f., Section Insensitivity to high dose irradiation). In squared brackets [x] the number of performed measurements is
stated. The bottom row (#7) presents calculated WEPL values.
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Figure 4 Transversal view of the spacer gel CT scan used for estimation of the HU value. Spacer gel was injected to the vial that was
positioned in the centre of the phantom.
Monte Carlo modelling of offline PET/CT-imaging of
positron emitters induced by scanned proton beams,
in preparation). As only the higher energetic beam
reached the gelatin volume, we concentrate here on
the results from this irradiation. The analysis of the
low-energy irradiation data yielded a phantom activa-
tion that was comparable to the one with the higher
energy but was restricted to the PMMA and gel sample
regions.
The pencil-beam irradiation of the phantom with a
total of 2.24 · 1011 protons took 215 s, while the subse-
quent phantom transport to the PET/CT scanner caused
a time delay of 176 s. Figure 5 (left) reports the lat-
erally integrated activity depth profile, normalised to
area. Due to a half-life of about 20 minutes, the decay
of 11C isotopes dominates the measured signal, result-
ing in a higher activity level in the PMMA regions
than in the gel and gelatin regions which are domi-
nated by the shorter lived 15O (T1/2 ≈ 2min.) playing
only a minor role in the reconstructed activity image
averaged over the total measurement frame time of 30
min. A good overall agreement is observed between
the measurement (c.f., Figure 5, red dashed line) and
the simulated expectation (c.f., Figure 5, blue dashed-
dotted line), especially with regard to the activation of
the gel sample and the beam range in this material of
interest.
In order to test the validity of the assumed chemical
gel composition, different isotope contributions to the
total measured activity are determined by the fit anal-
ysis described in Section Activity calculation and data
analysis. The resulting separated activity depth profiles
for 11C, 13N and 15O are presented in Figure 5 (right)
as area normalised distributions. Qualitatively, the fit-
ted activity fractions agree very well with the simulated
expectations, not only in the reference media PMMA and
gelatin but also in the gel sample region thus confirm-
ing a realistic material definition used for the simulation.
As an additional consistency check the activity distribu-
tion averaged over the measurement frame is calculated
from the sum of the separately fitted isotope contribu-
tions and compared to the distributions obtained from
the static data reconstruction and respective simulation in
Figure 5 (left).
Both analysis strategies, the static and the dynamic
data processing, have proven the validity of the assumed
qualitative gel properties in comparison to the activ-
ity simulation. The relative activity level observed in
the different materials agrees very well to the simu-
lated expectation of the frame averaged activity, which
is 11C dominated, as well as of the initial activity at the
start of the PET measurement, when the signal is domi-
nated by the decay of 15O. A slight offset of about 5% is
observed between the absolute activity values, which is,
however, consistent with the uncertainties of the dose cal-
ibration that was conducted more than 12 hours prior to
the actual measurement.
Discussion
Compatibility with the treatment planning system
During the measurement the water column was shifted
in 0.1mm steps, (ustep) which results in Bragg-Peak
determination uncertainty of comparable level (ufit).
The uncertainty in the manufacture of PMMA vial is
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Figure 5 Activity depth profiles as area normalised distributions. Left: laterally integrated depth profiles of the activity averaged over the
complete measurement frame (< A >) as obtained from the static data reconstruction (red, dashed), from the MC simulation (blue, dash-dotted),
and the sum of the fitted single isotope contributions (yellow, solid). Right: depth profiles of the initial activity at the PET measurement start (A0) as
extracted from the fit of the dynamically reconstructed PET data, compared to the simulated isotope yields (black lines), for 15O (yellow), 11C (red)
and 13N (blue).
0.05mm (uvial). These (ustep, ufit , uvial) result in uncer-
tainty in Bragg-Peak position determination within an
empty vial or vial filled with water of ± 0.2mmH2O
(2 σ ). The uncertainty of sample positioning was com-
pensated by application of offsets between the mea-
surement sessions. The gel injected to the vial did not
polymerise not in a homogeneous way but with some
air bubbles enclosed in the material (c.f., Figure 4),
which happens also when the material is implanted to
the patient. This inhomogeneity in the gel sample was
partially observed as a variation of the measured par-
ticle range after rotating the vial in the vial holder,
which is described by standard deviation of performed
measurements (usample).
To consider the fraction of air within the sample filled
with the spacer gel, one can assume that 3% of vial
volume was filled with air, which corresponds to 1mm
shift of Bragg-Peak in water and to WEPL change of
0.04. Apart from the prior error analyses, air fraction
in the sample might cause a significant (in comparison
with the other errors) systematic inaccuracy in range
measurement. However, this misalignment in the cal-
culation of WEPL of spacer gel material might cause
a desired convergence of measured WEPL point with
the HLUT.
The range of carbon ion beam in the gel is not exactly
equal to the one assumed by the TPS on the basis of the
CT image. The error in range calculation occurring during
the plan optimisation process is equal to the difference
in WEPL (0.017) between the measured (real) WEPL
(1.011±0.011) of the gel and the WEPL corresponding
to the measured HU value of the gel (1.028 WEPL for
HU=28.9). Assuming a typical particle beam penetration
depth of 40 mm in the homogeneous gel material, the esti-
mated dose distribution shift that may occur comes up to
0.65mm for the distal slices of a treatment plan. During
the treatment planning process the clinical target volume
(CTV) is extended to the planning target volume (PTV)
in order to cover uncertainties of the treatment delivery
technique. At HIT, a PTV safety margin of 5 to 7mm is
normally applied in the pelvic area. Dealing with the error
resulting from an application of spacer gel as a random
error (not the whole spacer gel implant is in the dose field,
the amount of the gel in the dose field depends on ran-
dom daily anatomy and positioning variations) we can add
it to the existing margins by calculating the root square of
the sum of the squares of possible dose shifts induced by
spacer gel and by other therapy uncertainties. This consid-
eration results in a maximal margin extension of 0.1mm.
As this uncertainty affects the prostate patient irradiation
marginally, it could be neglected for the creation of the
PTV.
Insensitivity to high dose irradiation
During sample irradiation lateral position of the beam and
dose deposited to the samples were monitored accord-
ing to the prescribed plan by the monitors of raster scan
system, as it is performed during the patient irradia-
tion. The irradiation field larger than the irradiated target,
exact laser positioning system and control radiographic
films guaranteed deposition of the prescribed dose in the
samples.
After an exposure to 150Gy photon irradiation, and
to 33Gy carbon ion and 91Gy proton irradiation Aug-
menix performed functional and chemical tests. The tests
included an evaluation of hydrogel swelling and time
to complete hydrolysis in accelerated conditions. Addi-
tionally, following hydrolysis, solutions were evaluated
with Nuclear Magnetic Resonance (NMR) spectrome-
try providing the information about the distribution of
chemical species contained in a sample and Gel Perme-
ation Chromatography (GPC) which is a chromatography
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method typically used for analysis of molecular weight of
polymers.
Augmenix reported that the high dose irradiation did
not impact the hydrogel swelling or hydrolysis rate,
demonstrating that the hydrogel network was not func-
tionally altered. Additionally, NMR and GPC analysis
performed on complete hydrolysed samples found no dif-
ferences in the irradiated and non-irradiated hydrogels,
suggesting that this level of irradiation does not result in
significant (in comparison with control sample) hydrogel
molecular rearrangement.
Role for PET-based treatment monitoring
The presented measurement of the proton-induced β+-
activity in the spacer gel sample confirms the assumed
material modelling. We were able to verify experimentally
the composition relevant for PET imaging by analysing the
produced positron emitter yield separated by isotope.
As the gel consists mainly of water, the activity induced
by the proton beam is dominated by the decay of 15O.
Due to the comparatively short half-life of this isotope
of about 2 minutes, most of this signal is lost dur-
ing the patient transfer from the treatment place to the
PET/CT device and necessary patient repositioning at
the scanner, which usually takes about 5–10 minutes,
depending on the complexity of the immobilisation equip-
ment and the patient’s condition. Therefore, the residual
activity in the spacer gel that can be detected in the
offline PET-measurement is expected to be rather low
compared to the activity level in the surrounding tis-
sue, where more 11C is produced. However, as the spacer
gel is a confined object delimited from the surround-
ing perfused tissue, the induced activity remains at the
production spot and is not affected by the biological
washout of the induced activity, which reduces signif-
icantly the measurable signal in well-perfused human
tissue region. Considering a typical prostate proton-
therapy fraction with a single RBE weighted dose of
3.3 Gy (RBE), the activity level detected in the spacer
gel area is about 300 Bq/ml, which is similar to the
signal observed in the surrounding low-perfused bony
and fatty structures, where washout plays only a minor
role. In case of carbon ion irradiation, the PET image
obtained offline is much less sensitive to the target
activation, since the signal is dominated by the 11C pro-
jectile fragments. Thus, the distal regions of the treat-
ment field exhibit a pronounced signal enhancement
with respect to the dose plateau region. As the spacer
gel is typically located at the edge of the distal dose
fall-off region of the single fields, the activation of the
gel is amplified by the projectile fragments stopped
inside the gel.
The performed investigations show that spacer gel irra-
diated with proton and carbon ion induces a signal
which can be obtained using the post-therapeutic PET-
imaging. Assuming stable position of the gel between
prostate and rectum over the whole therapy course, the
irradiation-induced activity within the spacer gel provides
additional information useful for validation of treatment
delivery with post-therapeutic PET-imaging for both pro-
ton and carbon ion irradiation. The additional reference
andmarker application of spacer gel would certainly bene-
fit from a higher carbon fraction in the material, such that
more 11C is generated, and from an optimised treatment
time course reducing the irradiation and treatment time
course.
Clinical aspects
The clinical and dosimetric advantages of the application
of spacer gel for photon therapy were already discussed
by Pinkawa et al. [11]. These are mainly a reduced dose
to the rectum and the potential for application of more
rigorous treatment planning objectives. The investiga-
tions presented in this paper show that the physical
changes in the spacer gel material during the therapy
course negligibly influence the irradiation of the prostate
target. Since spacer is a soft implant of tissue-like den-
sity and gel-consistency, there are justifiable presump-
tions that spacer gel may deform during the therapy
course. Pinkawa et al. [25] reports that the distance
between the prostate and anterior rectal wall is stable
when spacer gel is implanted before treatment planning.
The ion therapy is particularly sensitive on the anatomy
motion and deformations within the target and in the
beam entrance path. These effects cause range variations
and significantly influence the quality of irradiation [26]. It
is expected that the range variations caused by the motion
of the target, possible deformation of the spacer gel, or
density variations in the beam entrance path might influ-
ence the quality of irradiation of prostate patient to a
greater extent than the uncertainties caused by implanta-
tion of the spacer gel material. The quantitative analysis
of dosimetric effects of the application of spacer gel in
particle therapy in the presence of anatomical variations
in the target region is one of the main topics of ongoing
investigations at HIT in this field. The results of measure-
ments described in this document were a basis for the
application of spacer gel in the clinical study “Ion Prostate
Irradiation” (http://www.clinicaltrials.gov/) currently per-
formed at HIT (2012).
The application of the spacer gel would have an addi-
tional advantage if the gel had radio-opaque properties.
In radiation therapy gold markers implanted to the tis-
sue (i.e., prostate) are used to visualise the target by
pre-treatment control radiography or CT imaging. In
the same way, spacer gel with radio-opaque properties,
located in direct neighbourhood of the prostate, might
be used to indicate the position of the target or at least
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to recognise these treatment fraction, when anatomy
misalignments (filling of rectum or bladder different
than during treatment planning) would cause unac-
ceptable decrease of irradiation quality. Such products
were recently commissioned for clinical application by
Augmenix in US.
Conclusions
The performed investigations show that the range of car-
bon ions in spacer gel remain stable over the time interval
of ten weeks and under the exposure of a high dose of
33Gy (carbon ions), and 91Gy (protons), which is com-
parable to 100Gy (RBE) in patient. The spacer gel reveals
no physical changes after therapeutic doses of carbon ion
or proton irradiation. The penetration depth of these ions
is properly predicted by the treatment planning system
using computed tomography imaging that allows its safe
usage during the particle therapy of prostate cancer. The
application of the spacer gel implant in the close neigh-
bourhood of prostate is expected to allow higher doses
to the clinical target volume and to spare the most crit-
ical organ at risk. Further research on the composition
of spacer gel material might lead to additional clinical
benefits by a validation of prostate patient treatment via
PET-imaging or by patient positioning based on the gel
as a radio-opaque marker. Generally, the usage of soft
implants enlarging the space between the organs, not
being involved in biological processes and having the
function of a marker, could provide benefits for several
clinical aspects of radiation and particle therapy.
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